Cath Lab

The cardiac catheterization laboratory is used for diagnostic angiograms and percutaneous coronary interventions (PCI). Cath labs have also seen expanding use in recent years for transcatheter structural heart procedures. Some hospitals also share these labs with other subspecialties for catheter-based procedures in electrophysiology (EP), interventional radiology, peripheral artery disease (PAD), carotid and neuro interventional procedures and vascular surgery.

Thumbnail

A winning strategy for blood transfusions among anemic heart attack patients

Researchers detailed a method that improves patient safety and leads to significant cost savings.

peripheral vascular philips

Philips to acquire interventional device firm Intact Vascular for more than $275M

Around since 2011 and based in Wayne, Pennsylvania, the company specializes in treating peripheral artery disease.  

Thumbnail

Promising outcomes reported for transcatheter mitral valve-in-valve replacement

The overall procedural technical success rate, researchers reported, was 96.8%.

Thumbnail

Faster cath lab activation times make a big impact on patient care

Rapid reperfusion is linked to improved survival for STEMI patients, but delayed care is still prevalent. 

Thumbnail

Cath labs join forces, reduce radiation dose across the board

Cardiac cath labs can achieve significant radiation dose reductions through focused, collaborative quality improvement (QI) efforts, according to a new analysis published in Circulation: Cardiovascular Interventions.

Thumbnail

How should physicians treat STEMI patients with COVID-19? A new study aims to find out

A new international research study will focus on treatment strategies and outcomes of ST-segment elevation myocardial infarction (STEMI) patients with known or suspected COVID-19.

What the COVID-19 pandemic means for cath labs

The COVID-19 pandemic has changed the practice of cardiology as we know it, leading to supplies shortages, delayed procedures, and an at-risk patient population fearful of the road ahead. How has the outbreak affected cath labs?

Thumbnail

Orsiro stent continues to outperform Xience at 3 years

Three-year data from the BIOFLOW-V trial, presented Feb. 23 at the 2020 CRT Congress in National Harbor, Md., reinforce the status of Biotronik’s Orsiro drug-eluting stent as superior to the popular Xience stent.